DiaMedica Therapeutics Inc.
- DMAC
- NASDAQ
- Biotechnology
- Clinical-Stage Biotech (Neurology/Renal)
- Recombinant Protein Therapy
$7.57
Today −5.85%Quote Oct 16, 2026, 08:00 PM UTC
+10.51%over the last month
Max drawdown −10.1%From 1-month high −10.1%3 months +8.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$408.2M
Quote Oct 16
Next earnings
Nov 11
Expected, not confirmed
Analyst target
$8.33
+10.0% from here
Floor
$7.24
4.4% below price
Where the price sits
6 analysts
Analyst range, low to high
$7.00$10.00
- Price $7.57
- Resistance $7.78
- Consensus $8.33
The price is right under resistance. Analysts' average target sits about 10% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about DMACPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
35
Founded
2000